Abstract

Understanding the biological underpinning of relapse could improve the outcomes of patients with psychosis. Relapse is elicited by multiple reasons/triggers, but the consequence frequently accompanies deteriorations of brain function, leading to poor prognosis. Structural brain imaging studies have recently been pioneered to address this question, but a lack of molecular investigations is a knowledge gap. Following a criterion used for recent publications by others, we defined the experiences of relapse by hospitalization(s) due to psychotic exacerbation. We hypothesized that relapse-associated molecules might be underscored from the neurometabolites whose levels have been different between overall patients with early-stage psychosis and healthy subjects in our previous report. In the present study, we observed a significant decrease in the levels of N-acetyl aspartate in the anterior cingulate cortex and thalamus in patients who experienced relapse compared to patients who did not. Altogether, decreased N-acetyl aspartate levels may indicate relapse-associated deterioration of neuronal networks in patients.

Details

Title
Reduction of N-acetyl aspartate (NAA) in association with relapse in early-stage psychosis: a 7-Tesla MRS study
Author
Mihaljevic, Marina 1   VIAFID ORCID Logo  ; Chang, Yu-Ho 2 ; Witmer, Ashley M. 2 ; Coughlin, Jennifer M. 3   VIAFID ORCID Logo  ; Schretlen, David J. 3 ; Barker, Peter B. 4 ; Yang, Kun 3 ; Sawa, Akira 5   VIAFID ORCID Logo 

 Johns Hopkins University School of Medicine, Departments of Neuroscience, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins University School of Medicine, Departments of Psychiatry, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins University School of Medicine, Departments of Radiology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Johns Hopkins University School of Medicine, Departments of Neuroscience, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Departments of Psychiatry, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Departments of Biomedical Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Departments of Genetic Medicine, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Departments of Pharmacology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
Pages
29
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
2334265X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2933664047
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.